NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08)

Objective Salivary gland cancers (SGC) are rare cancers with currently no standard treatment for recurrent/metastatic disease. Based on checkpoint inhibitors benefit in a broad range of tumours, NIvolumab in Salivary gland CArcinoma of the Head and Neck (NISCAHN) evaluated nivolumab efficacy in SGC....

Full description

Bibliographic Details

Published in:	BMJ Oncology
Main Authors:	Christian Borel, Caroline Even, Christophe Le Tourneau, Jerome Fayette, Laurence Bozec, Joël Guigay, Sylvie Chabaud, Laurence Digue, Lionnel Geoffrois, Fréderic Rolland, Didier Cupissol, Anne Françoise Dillies, Sylvie Zanetta, Sophie Couchon-Thaunat, Valérie Costes-Martineau, Anne Sudaka-Bahadoran, Isabelle Jallut, Florence Garic, Audrey Lardy-Cleaud
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-12-01
Online Access:	https://bmjoncology.bmj.com/content/2/1/e000065.full